In summary, using a gp120-induced brain inflammation model in vivo, we have demonstrated that compounds with anti-inflammatory properties have the potential to prevent or reduce brain inflammation by interacting with signaling pathways. Here, ITIH4 is linked to brain inflammatory disease.